Addington, J, Stowkowy, J, Cadenhead, KS, Cornblatt, BA, Mcglashan, TH, Perkins, DO, Seidman, LJ, Tsuang, MT, Walker, EF and Woods, SW (2013) Early traumatic experiences in those at clinical high risk for psychosis. Early Intervention in Psychiatry 7, 300–305.
Appiah-Kusi, E, Leyden, E, Parmar, S, Mondelli, V, Mcguire, P and Bhattacharyya, S (2016) Abnormalities in neuroendocrine stress response in psychosis: the role of endocannabinoids. Psychological Medicine 46(1), 1–19.
Appiah-Kusi, E, Fisher, H, Petros, N, Wilson, R, Mondelli, V, Garety, P, Mcguire, P and Bhattacharyya, S (2017) Do cognitive schema mediate the association between childhood trauma and being at ultra-high risk for psychosis? Journal of Psychiatric Research 88, 89–96.
Barkus, EJ, Stirling, J, Hopkins, RS and Lewis, S (2006) Cannabis-induced psychosis-like experiences are associated with high schizotypy. Psychopathology 39, 175–178.
Bebbington, P, Jonas, S, Kuipers, E, King, M, Cooper, C, Brugha, T, Meltzer, H, Mcmanus, S and Jenkins, R (2011) Childhood sexual abuse and psychosis: data from a cross-sectional national psychiatric survey in England. The British Journal of Psychiatry 199, 29–37.
Bechdolf, A, Thompson, A, Nelson, B, Cotton, S, Simmons, M, Amminger, G, Leicester, S, Francey, S, Mcnab, C and Krstev, H (2010) Experience of trauma and conversion to psychosis in an ultra-high-risk (prodromal) group. Acta Psychiatrica Scandinavica 121, 377–384.
Bernstein, DP and Fink, L (1998) Childhood Trauma Questionnaire: A Retrospective Self-Report: Manual. San Antonio: Harcourt Brace & Company.
Bhattacharyya, S, Wilson, R, Appiah-Kusi, E, O'neill, A, Brammer, M, Perez, J, Murray, R, Allen, P, Bossong, MG and Mcguire, P (2018) Effect of cannabidiol on medial temporal, midbrain, and striatal dysfunction in people at clinical high risk of psychosis: a randomized clinical trial. JAMA Psychiatry 75, 1107–1117.
Bioque, M, García-Bueno, B, Macdowell, KS, Meseguer, A, Saiz, PA, Parellada, M, Gonzalez-Pinto, A, Rodriguez-Jimenez, R, Lobo, A, Leza, JC and Bernardo, M (2013) Peripheral endocannabinoid system dysregulation in first-episode psychosis. Neuropsychopharmacology 38, 2568.
Borgan, F, Veronese, M, O'daly, O, Marques, TR, Rogdaki, M and Howes, O (2018) Cannabinoid 1 receptor availability & memory function in first episode psychosis: a multi-modal PET fMRI study. Schizophrenia Bulletin 44, S291.
Ceccarini, J, De Hert, M, Van Winkel, R, Peuskens, J, Bormans, G, Kranaster, L, Enning, F, Koethe, D, Leweke, FM and Van Laere, K (2013) Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia. Neuroimage 79, 304–312.
Cohen, S, Kamarck, T and Mermelstein, R (1983) A global measure of perceived stress. Journal of Health and Social Behavior 24(4), 385–396.
Coid, J, Petruckevitch, A, Feder, G, Chung, W-S, Richardson, J and Moorey, S (2001) Relation between childhood sexual and physical abuse and risk of revictimisation in women: a cross-sectional survey. The Lancet 358, 450–454.
De Marchi, N, De Petrocellis, L, Orlando, P, Daniele, F, Fezza, F and Di Marzo, V (2003) Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids in Health and Disease 2, 5.
Di, S, Malcher-Lopes, R, Halmos, KC and Tasker, JG (2003) Nongenomic glucocorticoid inhibition via endocannabinoid release in the hypothalamus: a fast feedback mechanism. The Journal of Neuroscience 23, 4850–4857.
Di, S, Malcher-Lopes, R, Marcheselli, VL, Bazan, NG and Tasker, JG (2005 a) Rapid glucocorticoid-mediated endocannabinoid release and opposing regulation of glutamate and gamma-aminobutyric acid inputs to hypothalamic magnocellular neurons. Endocrinology 146, 4292–4301.
Di, S, Malcher-Lopes, R, Marcheselli, VL, Bazan, NG and Tasker, JG (2005 b) Rapid glucocorticoid-mediated endocannabinoid release and opposing regulation of glutamate and γ-aminobutyric acid inputs to hypothalamic magnocellular neurons. Endocrinology 146, 4292–4301.
Dlugos, A, Childs, E, Stuhr, KL, Hillard, CJ and De Wit, H (2012) Acute stress increases circulating anandamide and other N-acylethanolamines in healthy humans. Neuropsychopharmacology 37, 2416–2427.
D'souza, DC, Cortes-Briones, JA, Ranganathan, M, Thurnauer, H, Creatura, G, Surti, T, Planeta, B, Neumeister, A, Pittman, B and Normandin, MD (2016) Rapid changes in cannabinoid 1 receptor availability in cannabis-dependent male subjects after abstinence from cannabis. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging 1, 60–67.
Eggan, SM, Hashimoto, T and Lewis, DA (2008) Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia. Archives of General Psychiatry 65, 772–784.
Eggan, SM, Stoyak, SR, Verrico, CD and Lewis, DA (2010) Cannabinoid CB1 receptor immunoreactivity in the prefrontal cortex: comparison of schizophrenia and major depressive disorder. Neuropsychopharmacology 35, 2060–2071.
Fisher, HL, Appiah-Kusi, E and Grant, C (2012) Anxiety and negative self-schemas mediate the association between childhood maltreatment and paranoia. Psychiatry Research 196, 323–324.
Giuffrida, A, Parsons, L, Kerr, T, De Fonseca, FR, Navarro, M and Piomelli, D (1999) Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nature Neuroscience 2, 358.
Giuffrida, A, Leweke, FM, Gerth, CW, Schreiber, D, Koethe, D, Faulhaber, J, Klosterkötter, J and Piomelli, D (2004) Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 29, 2108.
Hill, M and Tasker, J (2012) Endocannabinoid signaling, glucocorticoid-mediated negative feedback, and regulation of the hypothalamic-pituitary-adrenal axis. Neuroscience 204, 5–16.
Hill, MN, Miller, GE, Carrier, EJ, Gorzalka, BB and Hillard, CJ (2009) Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress. Psychoneuroendocrinology 34, 1257–1262.
Howes, OD and Kapur, S (2009) The dopamine hypothesis of schizophrenia: version III – the final common pathway. Schizophrenia Bulletin 35, 549–562.
Koethe, D, Giuffrida, A, Schreiber, D, Hellmich, M, Schultze-Lutter, F, Ruhrmann, S, Klosterkötter, J, Piomelli, D and Leweke, FM (2009) Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. The British Journal of Psychiatry 194, 371–372.
Koethe, D, Pahlisch, F, Hellmich, M, Rohleder, C, Mueller, JK, Meyer-Lindenberg, A, Torrey, EF, Piomelli, D and Leweke, FM (2018) Familial abnormalities of endocannabinoid signaling in schizophrenia. The World Journal of Biological Psychiatry 20(2), 1–9.
Leweke, FM, Giuffrida, A, Wurster, U, Emrich, HM and Piomelli, D (1999) Elevated endogenous cannabinoids in schizophrenia. Neuroreport 10, 1665–1669.
Leweke, FM, Giuffrida, A, Koethe, D, Schreiber, D, Nolden, BM, Kranaster, L, Neatby, MA, Schneider, M, Gerth, CW and Hellmich, M (2007) Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophrenia Research 94, 29–36.
Leweke, F, Piomelli, D, Pahlisch, F, Muhl, D, Gerth, C, Hoyer, C, Klosterkötter, J, Hellmich, M and Koethe, D (2012) Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Translational Psychiatry 2, e94.
Leweke, FM, Mueller, JK, Lange, B and Rohleder, C (2016) Therapeutic potential of cannabinoids in psychosis. Biological Psychiatry 79, 604–612.
Malcher-Lopes, R, Di, S, Marcheselli, VS, Weng, F-J, Stuart, CT, Bazan, NG and Tasker, JG (2006) Opposing crosstalk between leptin and glucocorticoids rapidly modulates synaptic excitation via endocannabinoid release. The Journal of Neuroscience 26, 6643–6650.
Mizrahi, R (2015) Social stress and psychosis risk: common neurochemical substrates? Neuropsychopharmacology 41, 666.
Moore, TH, Zammit, S, Lingford-Hughes, A, Barnes, TR, Jones, PB, Burke, M and Lewis, G (2007) Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. The Lancet 370, 319–328.
Müller-Vahl, KR and Emrich, HM (2008) Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia. Expert Review of Neurotherapeutics 8, 1037–1048.
Petros, N, Foglia, E, Klamerus, E, Beards, S, Murray, R and Bhattacharyya, S (2016) Impact of childhood trauma on risk of relapse requiring psychiatric hospital admission for psychosis. British Journal of Psychiatry 209(2), 169–170. doi:10.1192/bjp.bp.115.176636.
Pruessner, M, Cullen, AE, Aas, M and Walker, EF (2017) The neural diathesis-stress model of schizophrenia revisited: an update on recent findings considering illness stage and neurobiological and methodological complexities. Neuroscience & Biobehavioral Reviews 73, 191–218.
Radua, J, Ramella-Cravaro, V, Ioannidis, JP, Reichenberg, A, Phiphopthatsanee, N, Amir, T, Yenn Thoo, H, Oliver, D, Davies, C and Morgan, C (2018) What causes psychosis? An umbrella review of risk and protective factors. World Psychiatry 17, 49–66.
Ranganathan, M, Cortes-Briones, J, Radhakrishnan, R, Thurnauer, H, Planeta, B, Skosnik, P, Gao, H, Labaree, D, Neumeister, A, Pittman, B, Surti, T, Huang, Y, Carson, RE and D'souza, DC (2016) Reduced brain cannabinoid receptor availability in schizophrenia. Biological Psychiatry 79, 997–1005.
Read, J (1997) Child abuse and psychosis: a literature review and implications for professional practice. Professional Psychology: Research and Practice 28, 448.
Read, J, Os, JV, Morrison, A and Ross, CA (2005) Childhood trauma, psychosis and schizophrenia: a literature review with theoretical and clinical implications. Acta Psychiatrica Scandinavica 112, 330–350.
Reuter, AR, Bumb, JM, Mueller, JK, Rohleder, C, Pahlisch, F, Hanke, F, Arens, E, Leweke, FM, Koethe, D and Schwarz, E (2017) Association of anandamide with altered binocular depth inversion illusion in schizophrenia. The World Journal of Biological Psychiatry 18, 483–488.
Sami, MB and Bhattacharyya, S (2018) Are cannabis-using and non-using patients different groups? Towards understanding the neurobiology of cannabis use in psychotic disorders. Journal of Psychopharmacology 32(8), 825–849.
Schoeler, T, Monk, A, Sami, MB, Klamerus, E, Foglia, E, Brown, R, Camuri, G, Altamura, AC, Murray, R and Bhattacharyya, S (2016 a) Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis. The Lancet Psychiatry 3(3), 215–225.
Schoeler, T, Petros, N, Di Forti, M, Klamerus, E, Foglia, E, Ajnakina, O, Gayer-Anderson, C, Colizzi, M, Quattrone, D and Behlke, I (2016 b) Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: an observational study. The Lancet Psychiatry 3, 947–953.
Schoeler, T, Petros, N, Di Forti, M, Pingault, J-B, Klamerus, E, Foglia, E, Small, A, Murray, R and Bhattacharyya, S (2016 c) Association between continued cannabis use and risk of relapse in first-episode psychosis: a quasi-experimental investigation within an observational study. JAMA Psychiatry 73, 1173–1179.
SPSS, I (2012) IBM SPSS Statistics Version 21. Boston, Mass: International Business Machines Corp.
Tzavara, ET, Li, DL, Moutsimilli, L, Bisogno, T, Di Marzo, V, Phebus, LA, Nomikos, GG and Giros, B (2006) Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications. Biological Psychiatry 59, 508–515.
Varese, F, Smeets, F, Drukker, M, Lieverse, R, Lataster, T, Viechtbauer, W, Read, J, Van Os, J and Bentall, RP (2012) Childhood adversities increase the risk of psychosis: a meta-analysis of patient-control, prospective- and cross-sectional cohort studies. Schizophrenia Bulletin 38(4), 661–671.
Volk, DW, Eggan, SM, Horti, AG, Wong, DF and Lewis, DA (2014) Reciprocal alterations in cortical cannabinoid receptor 1 binding relative to protein immunoreactivity and transcript levels in schizophrenia. Schizophrenia Research 159(1), 124–129.
Walker, EA, Unutzer, J, Rutter, C, Gelfand, A, Saunders, K, VonKorff, M, Koss, MP and Katon, W (1999) Costs of health care use by women hmo members with a history of childhood abuse and neglect. Archives of General Psychiatry 56, 609–613.
Wong, DF, Kuwabara, H, Horti, AG, Raymont, V, Brasic, J, Guevara, M, Ye, W, Dannals, RF, Ravert, HT and Nandi, A (2010) Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C] OMAR. Neuroimage 52, 1505–1513.
Yung, AR, Phillips, LJ, Mcgorry, PD, Mcfarlane, CA, Francey, S, Harrigan, S, Patton, GC and Jackson, HJ (1998) Prediction of psychosis: a step towards indicated prevention of schizophrenia. The British Journal of Psychiatry 172(S33), 14–20.
Yung, AR, Yung, AR, Pan Yuen, H, Mcgorry, PD, Phillips, LJ, Kelly, D, Dell'olio, M, Francey, SM, Cosgrave, EM and Killackey, E (2005) Mapping the onset of psychosis: the comprehensive assessment of at-risk mental states. Australian & New Zealand Journal of Psychiatry 39, 964–971.